NKGen Biotech (NKGN) Stock Analysis: AI Score & Alternative Data
Demand signals are heating up for NKGen Biotech
Is NKGen Biotech a buy right now? The alternative data says hold. This NKGN stock analysis is built on the 25+ alternative data signals AltIndex tracks on NKGen Biotech every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 49/100: a Hold. The stock trades at $0.00 with a $8M market cap.
The data leans positive over the past 90 days — Instagram followers up 32.6% to 3K followers — but the move hasn’t been broad enough to lift NKGN into buy territory yet.
NKGN’s broader alt-data profile also covers headcount (53 employees, according to LinkedIn), and web traffic (3K monthly visits). Every signal links to its own page with full history, the NKGN technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on NKGN is just below.
NKGen Biotech AI Stock Analysis
NKGen Biotech is a leading biopharmaceutical company specializing in the development of natural killer (NK) cell therapies. These therapies aim to harness the power of the immune system to treat cancer and other diseases. NKGen Biotech is driven by innovation and a commitment to progressing cutting-edge treatments to address unmet medical needs.
Analysis generated September 1, 2026.
Recent NKGen Biotech Stock Alerts
|
NKGen Biotech | September 3 Price is down by -79% in the last 24h. |
|
NKGen Biotech | September 1 Over the past few months, there has been a noticeable upward trend in Instagram Followers. |
|
NKGen Biotech | August 31 Price is up by 3710% in the last 24h. |
|
NKGen Biotech | August 25 Price is down by -58.8% in the last 24h. |
NKGen Biotech Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 3K | 4.7% | |
| Job Posts | 0 | N/A | |
| LinkedIn Employees | 53 | 3.6% | |
| Reddit Mentions | 0 | N/A | |
| Stocktwits Mentions | 3 | 50.0% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 1K | 3.6% | |
| X Followers | 314 | 0% | |
| Instagram Followers | 3K | 32.6% | |
| Facebook Followers | 1K | 0.5% | |
| Facebook Engagement | 0 | N/A |
About NKGen Biotech (NKGN)
NKGen Biotech, Inc. is a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. The company is headquartered in Santa Ana, California.
| Price | $0.00 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $8M |
| Year Range | $0 – $0 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest NKGen Biotech News
View more →
NKGen Biotech to Present at the 2026 BIOCHINA Global Forum on Troculeucel’s Potential in Alzheimer’s Disease and Other Neurodegenerative ConditionsJuly 2 - GlobeNewswire |
|
NKGen Biotech Expands Clinical Trial Site Network for Alzheimer’s Disease Program Across U.S. to Improve Patient Access and Support EnrollmentMay 19 - GlobeNewswire |
|
 |
Osteosarcoma Market is Set to Rise by 2036 as 8 Emerging Therapies Set to Drive Future Growth | DelveInsightSeptember 3 - PRNewswire |
 |
The Next Billion-Dollar Opportunity in Alzheimer's Disease Market: 6 Pipeline Therapies to Watch | DelveInsightAugust 6 - PRNewswire |
See NKGen Biotech’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for NKGN, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREENKGen Biotech Earnings & Financial Performance
View all earnings →NKGen Biotech Insider Trading Activity
View all →| CHERNG PEGGY filed to sell 21,752,885 shares at $0.0. May 27 '25 |
| CHERNG PEGGY filed to sell 39,339,103 shares at $0.0. May 27 '25 |
| Song Paul Y. filed to sell 21,020,846 shares at $0.0. May 5 '25 |
| Song Paul Y. filed to sell 41,699,449 shares at $0.0. May 5 '25 |
NKGen Biotech Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to NKGen Biotech
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
OSR HoldingsOSRH |
$0.20 8.7% | $8M | 53 |
 |
Mainz BiomedMYNZ |
$0.84 2.1% | $8M | 48 |
 |
SoligenixSNGX |
$0.36 1.9% | $8M | 36 |
 |
Brainstorm CellBCLI |
$1.03 3.0% | $8M | 46 |
 |
Alzamend NeuroALZN |
$1.70 1.2% | $8M | 42 |
Explore NKGen Biotech Data
Frequently Asked Questions: NKGen Biotech (NKGN)
NKGen Biotech has an AltIndex AI Score of 49/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
49/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of NKGen Biotech (NKGN) stock is $0.00 with a market cap of $8M.
As of today, NKGen Biotech’s PE (Price to Earnings) ratio is —.
View the latest NKGen Biotech insider transactions to see recent buying and selling activity by company executives and directors.
Check the NKGen Biotech congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The NKGN stock price chart above shows NKGen Biotech’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full NKGen Biotech technical analysis for RSI, moving averages, and more.
See the stocks similar to NKGen Biotech section on this page for companies in the same industry ranked by market cap and AI Score.
